Acute renal failure following the use of rosiglitazone in a chronic kidney disease patient

Singapore Medical Journal

Volumn 50, Issue 1, 2009, Pages

  Abdul Ghani, R ^a,b   Zainudin, S ^a   Kamaruddin, N A ^a   Kong, N C T ^a  

^a DEPARTMENT OF PHARMACOLOGY   (Malaysia)

^b Tropicana Medical Centre   (Malaysia)

Author keywords

Acute interstitial nephritis; Acute renal failure; Mycophenolate mofetil; Peroxisome proliferator activated receptor gamma; Rosiglitazone; Thiazolidinediones

Indexed keywords

ACARBOSE; ALLOPURINOL; AMLODIPINE; ATENOLOL; FELODIPINE; FENOFIBRATE; GLICLAZIDE; METFORMIN; MINOXIDIL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL ANTIDIABETIC AGENT; PRAZOSIN; ROSIGLITAZONE;

ACUTE KIDNEY FAILURE; AGED; ANAMNESIS; ARTICLE; BLOATING; CASE REPORT; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; DIABETES MELLITUS; DRUG RESPONSE; DRUG WITHDRAWAL; DUODENUM ULCER; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEMODIALYSIS; HISTOPATHOLOGY; HUMAN; HYPERTENSION; INTERSTITIAL NEPHRITIS; KIDNEY BIOPSY; MALE; PRESCRIPTION;

ACUTE KIDNEY INJURY; AGED; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; MALE; MYCOPHENOLIC ACID; RENAL DIALYSIS; THIAZOLIDINEDIONES;

EID: 62649154715     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368:1096-105.
2. Azen SP, Peters RK, Berkowitz K, et al. TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo - controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin Trials 1998; 19:217-31.
3. Xiang AH, Peters RK, Kjos SL, et al. Continued protection from diabetes during treatment of the TRIPOD Cohort with pioglitazone. In: New Orleans, LA: Proceedings of the 63rd Annual Meeting of the American Diabetes Association; 2003 June 13-17. Abstract 322-OR.
4. Viberti G, Kahn SE, Greene DA, et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002; 25:1737-43.
5. Dormandy J, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial in macroVascular Events): a randomised controlled trial. Lancet 2005; 366:1279-89.
6. Castledine C, Wright D, Kingdon E. Rosiglitazone as a cause of acute interstitial nephritis. Nephrol Dial Transplant 2006; 21:1994-5.
7. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356:1-15.
8. Cheng AYY, Fantus IG. Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ 2005; 172:213-26.
9. Calkin AC, Allen TJ. Diabetes mellitus-associated atherosclerosis. Mechanisms involved and potential for pharmacological invention. Am J Cardiovasc Drugs 2006; 6:15-40.
10. Schernthaner G. Kidney disease in diabetology. Nephrol Dial Transplant 2007; 22:703-7.
11. Rossert J. Drug-induced acute interstitial nephritis. Kidney Int 2001; 60:804-17.
12. Preddie DC, Markowitz GS, Radhakrishnan J, et al. Mycophenolate mofetil for the treatment of interstitial nephritis. Clin J Am Soc Nephrol 2006; 1:718-22.